Ownership and insider activity for Atea Pharmaceuticals, Inc. (AVIR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Price
| Price | $5.15 |
| Market Cap | $412M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-18 | Lucidi Bruno | M-Exempt | 29,600 | |
| 2026-06-18 | Lucidi Bruno | A-Award | 37,700 | $164K |
| 2026-06-18 | Lucidi Bruno | A-Award | 26,700 | |
| 2026-06-18 | Lucidi Bruno | M-Exempt | 29,600 | |
| 2026-06-18 | BERGER FRANKLIN M | M-Exempt | 29,600 | |
| 2026-06-18 | BERGER FRANKLIN M | A-Award | 37,700 | $164K |
| 2026-06-18 | BERGER FRANKLIN M | A-Award | 26,700 | |
| 2026-06-18 | BERGER FRANKLIN M | M-Exempt | 29,600 | |
| 2026-06-18 | Berman Howard | A-Award | 37,700 | $164K |
| 2026-06-18 | Berman Howard | A-Award | 26,700 |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.5M | $21.7M | $850.1M | $764.4M | $646.7M | $143.8M | $64.7M | $95.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $434.3M | $390.0M | $206.1M |
| Receivables | 0 | 0 | $5.8M | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $34.7M | $21.9M | $863.5M | $772.4M | $660.9M | $590.5M | $462.4M | $311.0M |
| Property, Plant & Equipment | $56000 | $41000 | $48000 | $184000 | $4.1M | $3.1M | $2.1M | $1.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $34.9M | $22.1M | $863.6M | $772.9M | $666.7M | $595.0M | $464.7M | $315.2M |
| Accounts Payable | $391000 | $548000 | $60000 | $4.5M | $2.6M | $4.3M | $4.5M | $12.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $843000 |
| Total Current Liabilities | $1.8M | $2.4M | $315.8M | $56.9M | $18.5M | $32.4M | $18.6M | $39.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $71.0M | $2.5M | $315.8M | $62.8M | $26.1M | $39.8M | $25.8M | $39.8M |
| Retained Earnings | -$40.2M | -$54.2M | -$65.2M | $56.0M | -$59.9M | -$195.8M | -$364.2M | -$522.6M |
| Total Equity | -$36.2M | $19.5M | $547.8M | $710.1M | $640.6M | $555.2M | $438.9M | $275.4M |
| Total Debt | 0 | 0 | 0 | $197000 | $3.1M | $2.4M | $1.6M | $843000 |
| Net Debt | -$34.5M | -$21.7M | -$850.1M | -$764.2M | -$643.6M | -$575.7M | -$453.1M | -$301.0M |
| Working Capital | $32.9M | $19.5M | $547.7M | $715.5M | $642.4M | $558.1M | $443.8M | $271.2M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.13 |
Profitability
| Return on Equity | -64.25% |
| Return on Invested Capital | -86.35% |
| Return on Assets | -71.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ALLO · ARCT · ENTA · HUMA · PYXS · TRDA
Explore sector: Healthcare · Biotechnology
More sections of AVIR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks